On June 17, 2025, Immuneering Corp announced encouraging interim results from its Phase 2a trial of atebimetinib for pancreatic cancer, showing an 81% disease control rate and a 39% overall response rate among 36 patients. The trial reported a 94% overall survival and a 72% progression-free survival at a six-month follow-up, with plans to initiate a pivotal trial in 2026 pending regulatory feedback.